$BPMC News
Last published 3w ago
- 3w agoBPMCApproval of Ayvakit, Nda #212608 (Efficacy)FDA Approved DrugsApproval Date: 10/16/2026; Drug Name: Ayvakit, Nda #212608; Active Ingredients: AVAPRITINIB; Company: Blueprint Medicines; Submission Status: Approval; Submission Classification: Efficacy; Application Number: 212608
- 1y agoBPMCBlueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI CongressesPR NewswireBlueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations reflecting over a decade of collaboration with clinical experts and ...
- 1y agoSNYAboBPMCSanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunologyPR NewswireSanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis...
- 1y agoBPMCBlueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue GuidancePR NewswireBlueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the first quarter ended March 31,...
- 1y agoBPMCBlueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025PR NewswireBlueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May...
- 1y agoBPMCBlueprint Medicines to Present at 24th Annual Needham Virtual Healthcare ConferencePR NewswireBlueprint Medicines Corporation (NASDAQ: BPMC) today announced that company management will participate virtually in a fireside chat at the 24th...
- 1y agoBPMCBlueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint CongressPR NewswireBlueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations reflecting its ongoing efforts to innovate the treatment of mast...
- 1y agoBPMCBlueprint Medicines Reports Fourth Quarter and Full Year 2024 ResultsPR NewswireBlueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the fourth quarter and full year...
- 1y agoBPMCBlueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025PR NewswireBlueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday,...
- 1y agoBPMCBlueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued GrowthPR NewswireBlueprint Medicines Corporation (Nasdaq: BPMC) today provided a 2025 corporate outlook and strategy for continued growth leveraging the company's...
- 1y agoBPMCBlueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare ConferencePR NewswireBlueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland, Chief Executive Officer, will present a corporate overview and...
- 1y agoBPMCBlueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual MeetingPR NewswireBlueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations that continue to demonstrate the long-term clinical benefits of...
- 2y agoBPMCApproval of Ayvakit, Nda #212608 (Labeling)FDA Approved DrugsApproval Date: 11/08/2024; Drug Name: Ayvakit, Nda #212608; Active Ingredients: AVAPRITINIB; Company: Blueprint Medicines; Submission Status: Approval; Submission Classification: Labeling; Application Number: 212608
- 2y agoBPMCBlueprint Medicines Corporation (BPMC) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoBPMCBlueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue GuidancePR NewswireBlueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the third quarter ended Sept 30,...
- 2y agoBPMCBlueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024PR NewswireBlueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday,...
- 2y agoBPMCBlueprint Medicines to Present at Upcoming Investor ConferencesPR NewswireBlueprint Medicines Corporation (NASDAQ: BPMC) today announced its participation in the following upcoming virtual investor conferences: Stifel 2024...
- 2y agoBPMCBlueprint Medicines Corporation (BPMC) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoBPMCBlueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue GuidancePR NewswireBlueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the second quarter ended June 30,...
- 2y agoBPMCBlueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024PR NewswireBlueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday,...
- 2y agoBPMCBlueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)PR NewswireBlueprint Medicines Corporation (Nasdaq: BPMC) today announced multiple upcoming datasets across two key conferences that reinforce the significant...
- 2y agoBPMCBlueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual MeetingPR NewswireBlueprint Medicines Corporation (Nasdaq: BPMC) today announced updated data from the ongoing Phase 1 dose escalation portion of the VELA clinical...
- 2y agoBPMCBlueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireBlueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective May 1, 2024, the Compensation Committee of Blueprint Medicines' Board ...
- 2y agoBPMCBlueprint Medicines Corporation (BPMC) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoBPMCBlueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue GuidancePR NewswireBlueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the first quarter ended March 31,...
- 2y agoBPMCBlueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024PR NewswireBlueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May...
- 2y agoBPMCBlueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted TherapeuticsPR NewswireBlueprint Medicines Corporation (NASDAQ: BPMC) today announced it will launch a webcast series to provide scientific perspectives and showcase the...
- 2y agoBPMCBlueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireBlueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective April 1, 2024, the Compensation Committee of Blueprint Medicines'...
- 2y agoBPMCBlueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireBlueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective March 1, 2024, the Compensation Committee of Blueprint Medicines'...
- 2y agoBPMCBlueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual MeetingPR NewswireBlueprint Medicines Corporation (Nasdaq: BPMC) today announced PIONEER trial results highlighting the long-term efficacy and safety of AYVAKIT®...
- 2y agoBPMCBlueprint Medicines Corporation (BPMC) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoBPMCBlueprint Medicines Reports Fourth Quarter and Full Year 2023 ResultsPR NewswireBlueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the fourth quarter and full year...
- 2y agoBPMCBlueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireBlueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective February 1, 2024, the Compensation Committee of Blueprint Medicines'...
- 2y agoBPMCBlueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024PR NewswireBlueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday,...
- 2y agoBPMCBlueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare ConferencePR NewswireBlueprint Medicines Corporation (Nasdaq: BPMC) today outlined its 2024 corporate strategy to deliver accelerated revenue growth, sustainable research ...
- 2y agoBPMCBlueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireBlueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective January 1, 2023, the Compensation Committee of Blueprint Medicines'...
- 2y agoBPMCBlueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare ConferencePR NewswireBlueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland, Chief Executive Officer, will present a corporate overview and...
- 2y agoBPMCBlueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic MastocytosisPR NewswireBlueprint Medicines Corporation (Nasdaq: BPMC) today announced the European Commission has approved AYVAKYT® (avapritinib) for the treatment of adult ...
- 2y agoBPMCBlueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual MeetingPR NewswireBlueprint Medicines Corporation (Nasdaq: BPMC) today announced data showcasing its commitment to advance the scientific understanding and treatment...
- 2y agoBPMCBlueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireBlueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective December 1, 2023, the Compensation Committee of Blueprint Medicines'...
- 2y agoBPMCBlueprint Medicines to Present at JMP Securities Hematology and Oncology SummitPR NewswireBlueprint Medicines Corporation (Nasdaq: BPMC) today announced that company management will participate virtually in a fireside chat at the JMP...
- 3y agoBPMCBlueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic MastocytosisPR NewswireBlueprint Medicines Corporation (Nasdaq: BPMC) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...
- 3y agoBPMCBlueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireBlueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective November 1, 2023, the Compensation Committee of Blueprint Medicines'...
- 3y agoBPMCBlueprint Medicines Reports Third Quarter 2023 ResultsPR NewswireBlueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the third quarter ended September...
- 3y agoANIXIMGNGLYCBPMCAnixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory BoardPR NewswireAnixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today...
- 3y agoBPMCBlueprint Medicines to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023PR NewswireCAMBRIDGE, Mass., Oct. 12, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, October 26, 2023, to report
- 3y agoBPMCBlueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireCAMBRIDGE, Mass., Oct. 5, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), today announced that, effective October 1, 2023, the Compensation Committee of Blueprint Medicines' Board of Directors
- 3y agoBPMCBlueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireCAMBRIDGE, Mass., Sept. 5, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), today announced that, effective September 1, 2023, the Compensation Committee of Blueprint Medicines' Board of Directors
- 3y agoBPMCBlueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireCAMBRIDGE, Mass., Aug. 4, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), today announced that, effective August 1, 2023, the Compensation Committee of Blueprint Medicines' Board of Directors
- 3y agoBPMCBlueprint Medicines to Report Second Quarter 2023 Financial Results on Wednesday, August 2, 2023PR NewswireCAMBRIDGE, Mass., July 19, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, August 2, 2023, to report